Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures
Version of Record online: 15 FEB 2008
© 2008 The Authors
British Journal of Clinical Pharmacology
Volume 65, Issue 5, pages 737–741, May 2008
How to Cite
Ramsay, J., Wright, C., Thompson, R., Hull, D. and Morice, A. H. (2008), Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. British Journal of Clinical Pharmacology, 65: 737–741. doi: 10.1111/j.1365-2125.2008.03115.x
- Issue online: 15 FEB 2008
- Version of Record online: 15 FEB 2008
- Received 2 May 2006Accepted16 November 2007Published OnlineEarly15 February 2008
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Dextromethorphan is widely used as a cough suppressant in over the counter medications.
• Its efficacy in altering cough reflex sensitivity has been shown in healthy volunteers. In contrast evidence for an effect on clinically important cough is poor.
WHAT THIS STUDY ADDS
• A significant decrease in evoked cough was seen with dextromethorphan compared with placebo. However, both placebo and active treatment improved subjective data to a similar degree.
• We doubt the validity of currently used objective tests in the investigation of antitussives.
Using an established model of smokers cough we measured the antitussive effects of dextromethorphan compared with placebo.
The study was a randomized, double-blind placebo controlled, crossover comparison of 22 mg 0.8 ml−1 dextromethorphan delivered pregastrically with matched placebo. Objective and subjective measurements of cough were recorded. Subjective measures included a daily diary record of cough symptoms and the Leicester quality of life questionnaire. Cough frequency was recorded using a manual cough counter. The objective measure of cough reflex sensitivity was the citric acid, dose–response cough challenge.
Dextromethorphan was significantly associated with an increase in the concentration of citric acid eliciting an average of two coughs/inhalation (C2) when compared with placebo, 1 h post dose by 0.49 mM (95% CI 0.05, 0.45, geometric mean 3.09) compared with placebo 0.24 mM (geometric mean 1.74) P < 0.05 and at 2 h 0.57 mM (95% CI 0.01, 0.43, geometric mean 3.75) compared with placebo 0.34 mM (geometric mean 2.19) P < 0.05). There was a highly significant improvement in the subjective data when compared with baseline. However, there was no significant difference between placebo and active treatment. No correlation was seen between cough sensitivity to citric acid and recorded cough counts or symptoms. When both subjective and objective data were compared with screening data there was evidence of a marked ‘placebo’ effect.
The objective measure of cough sensitivity demonstrates dextromethorphan effectively diminishes the cough reflex sensitivity. However, subjective measures do not support this. Other studies support these findings, which may represent a profound sensitivity of the cough reflex to higher influences.